Cargando…
A new mouse model of ADHD for medication development
ADHD is a major societal problem with increasing incidence and a stagnant track record for treatment advances. A lack of appropriate animal models has partly contributed to the incremental advance of this field. Hence, our goal was to generate a novel mouse model that could be useful for ADHD medica...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5171883/ https://www.ncbi.nlm.nih.gov/pubmed/27996970 http://dx.doi.org/10.1038/srep39472 |
_version_ | 1782484032744849408 |
---|---|
author | Majdak, Petra Ossyra, John R. Ossyra, Jessica M. Cobert, Adam J. Hofmann, Gabrielle C. Tse, Stephen Panozzo, Brent Grogan, Elizabeth L. Sorokina, Anastassia Rhodes, Justin S. |
author_facet | Majdak, Petra Ossyra, John R. Ossyra, Jessica M. Cobert, Adam J. Hofmann, Gabrielle C. Tse, Stephen Panozzo, Brent Grogan, Elizabeth L. Sorokina, Anastassia Rhodes, Justin S. |
author_sort | Majdak, Petra |
collection | PubMed |
description | ADHD is a major societal problem with increasing incidence and a stagnant track record for treatment advances. A lack of appropriate animal models has partly contributed to the incremental advance of this field. Hence, our goal was to generate a novel mouse model that could be useful for ADHD medication development. We reasoned that hyperactivity is a core feature of ADHD that could easily be bred into a population, but to what extent other hallmark features of ADHD would appear as correlated responses was unknown. Hence, starting from a heterogeneous population, we applied within-family selection over 16 generations to produce a High-Active line, while simultaneously maintaining an unselected line to serve as the Control. We discovered that the High-Active line demonstrated motor impulsivity in two different versions of the Go/No-go test, which was ameliorated with a low dose of amphetamine, and further displayed hypoactivation of the prefrontal cortex and dysregulated cerebellar vermal activation as indexed by c-Fos immunohistochemical staining. We conclude that the High-Active line represents a valid model for the Hyperactive-Impulsive subtype of ADHD and therefore may be used in future studies to advance our understanding of the etiology of ADHD and screen novel compounds for its treatment. |
format | Online Article Text |
id | pubmed-5171883 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-51718832016-12-28 A new mouse model of ADHD for medication development Majdak, Petra Ossyra, John R. Ossyra, Jessica M. Cobert, Adam J. Hofmann, Gabrielle C. Tse, Stephen Panozzo, Brent Grogan, Elizabeth L. Sorokina, Anastassia Rhodes, Justin S. Sci Rep Article ADHD is a major societal problem with increasing incidence and a stagnant track record for treatment advances. A lack of appropriate animal models has partly contributed to the incremental advance of this field. Hence, our goal was to generate a novel mouse model that could be useful for ADHD medication development. We reasoned that hyperactivity is a core feature of ADHD that could easily be bred into a population, but to what extent other hallmark features of ADHD would appear as correlated responses was unknown. Hence, starting from a heterogeneous population, we applied within-family selection over 16 generations to produce a High-Active line, while simultaneously maintaining an unselected line to serve as the Control. We discovered that the High-Active line demonstrated motor impulsivity in two different versions of the Go/No-go test, which was ameliorated with a low dose of amphetamine, and further displayed hypoactivation of the prefrontal cortex and dysregulated cerebellar vermal activation as indexed by c-Fos immunohistochemical staining. We conclude that the High-Active line represents a valid model for the Hyperactive-Impulsive subtype of ADHD and therefore may be used in future studies to advance our understanding of the etiology of ADHD and screen novel compounds for its treatment. Nature Publishing Group 2016-12-20 /pmc/articles/PMC5171883/ /pubmed/27996970 http://dx.doi.org/10.1038/srep39472 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Majdak, Petra Ossyra, John R. Ossyra, Jessica M. Cobert, Adam J. Hofmann, Gabrielle C. Tse, Stephen Panozzo, Brent Grogan, Elizabeth L. Sorokina, Anastassia Rhodes, Justin S. A new mouse model of ADHD for medication development |
title | A new mouse model of ADHD for medication development |
title_full | A new mouse model of ADHD for medication development |
title_fullStr | A new mouse model of ADHD for medication development |
title_full_unstemmed | A new mouse model of ADHD for medication development |
title_short | A new mouse model of ADHD for medication development |
title_sort | new mouse model of adhd for medication development |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5171883/ https://www.ncbi.nlm.nih.gov/pubmed/27996970 http://dx.doi.org/10.1038/srep39472 |
work_keys_str_mv | AT majdakpetra anewmousemodelofadhdformedicationdevelopment AT ossyrajohnr anewmousemodelofadhdformedicationdevelopment AT ossyrajessicam anewmousemodelofadhdformedicationdevelopment AT cobertadamj anewmousemodelofadhdformedicationdevelopment AT hofmanngabriellec anewmousemodelofadhdformedicationdevelopment AT tsestephen anewmousemodelofadhdformedicationdevelopment AT panozzobrent anewmousemodelofadhdformedicationdevelopment AT groganelizabethl anewmousemodelofadhdformedicationdevelopment AT sorokinaanastassia anewmousemodelofadhdformedicationdevelopment AT rhodesjustins anewmousemodelofadhdformedicationdevelopment AT majdakpetra newmousemodelofadhdformedicationdevelopment AT ossyrajohnr newmousemodelofadhdformedicationdevelopment AT ossyrajessicam newmousemodelofadhdformedicationdevelopment AT cobertadamj newmousemodelofadhdformedicationdevelopment AT hofmanngabriellec newmousemodelofadhdformedicationdevelopment AT tsestephen newmousemodelofadhdformedicationdevelopment AT panozzobrent newmousemodelofadhdformedicationdevelopment AT groganelizabethl newmousemodelofadhdformedicationdevelopment AT sorokinaanastassia newmousemodelofadhdformedicationdevelopment AT rhodesjustins newmousemodelofadhdformedicationdevelopment |